- Home
- CHRS vs MGF Comparison
CHRS vs MGF Comparison
Compare CHRS & MGF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- MGF
- Stock Information
- Founded
- CHRS 2010
- MGF 1987
- Country
- CHRS United States
- MGF United States
- Employees
- CHRS N/A
- MGF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- MGF Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- MGF Finance
- Exchange
- CHRS Nasdaq
- MGF Nasdaq
- Market Cap
- CHRS 102.0M
- MGF 100.1M
- IPO Year
- CHRS 2014
- MGF N/A
- Fundamental
- Price
- CHRS $1.04
- MGF $3.04
- Analyst Decision
- CHRS Buy
- MGF
- Analyst Count
- CHRS 3
- MGF 0
- Target Price
- CHRS $4.68
- MGF N/A
- AVG Volume (30 Days)
- CHRS 1.3M
- MGF 104.4K
- Earning Date
- CHRS 08-07-2025
- MGF 01-01-0001
- Dividend Yield
- CHRS N/A
- MGF 7.64%
- EPS Growth
- CHRS N/A
- MGF N/A
- EPS
- CHRS N/A
- MGF N/A
- Revenue
- CHRS $272,251,000.00
- MGF N/A
- Revenue This Year
- CHRS N/A
- MGF N/A
- Revenue Next Year
- CHRS $99.43
- MGF N/A
- P/E Ratio
- CHRS $2.44
- MGF N/A
- Revenue Growth
- CHRS 19.87
- MGF N/A
- 52 Week Low
- CHRS $0.66
- MGF $2.91
- 52 Week High
- CHRS $2.43
- MGF $3.46
- Technical
- Relative Strength Index (RSI)
- CHRS 68.96
- MGF 40.23
- Support Level
- CHRS $0.88
- MGF $3.07
- Resistance Level
- CHRS $1.06
- MGF $3.11
- Average True Range (ATR)
- CHRS 0.07
- MGF 0.03
- MACD
- CHRS 0.02
- MGF -0.00
- Stochastic Oscillator
- CHRS 93.38
- MGF 0.00
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About MGF MFS Government Markets Income Trust
MFS Government Markets Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income. The fund invests a majority of the net assets, including borrowings for investment purposes, in U.S. and foreign government securities. The company invest various sectors like U.S. Treasury Securities, Mortgage-Backed Securities, Investment Grade Corporates, Municipal Bonds, Non-U.S. Government Bonds, etc, out of which maximum revenue is gained from U.S. Treasury Securities.